List of phase III cancer clinical trials, 2015
compound |
cancer type |
reference |
companies involved |
|---|---|---|---|
Abemaciclib |
breast cancer, lung cancer |
||
Atezolizumab |
bladder cancer |
Genentech, Roche |
|
Alectinib |
lung cancer |
||
Ruxolitinib |
pancreatic cancer |
||
Avelumab |
non-small-cell lung cancer |
||
RHB-104 |
gastrointestinal cancer |
RedHill Biopharma |
|
Vicinium |
bladder cancer |
Viventia |
|
Cetuximab |
colorectal cancer |
||
eltrapuldencel-T |
melanoma |
Caladrius Biosciences |
|
Panitumumab |
colorectal cancer |
||
Olaratumab |
sarcoma |
||
Pertuzumab |
breast cancer |
Genentech |
|
AGS-003 |
renal cell carcinoma |
Argos Therapeutics |
|
Rociletinib |
non-small-cell lung cancer |
||
Niraparib |
ovarian cancer |
||
Sunitinib |
small-cell lung cancer |
||
Pazopanib |
ovarian cancer |
||
nelipepimut-s |
breast cancer |
||
Xilonix |
colorectal cancer |
||
Cabozantinib |
prostate cancer |
||
Bevacizumab |
lung cancer |
||
Rucaparib |
ovarian cancer |
Clovis Oncology |
|
Ganetespib |
lung cancer |
||
Copanlisib |
non-Hodgkin lymphoma |
||
Palbociclib |
breast cancer |
||
Selumetinib |
melanoma |
||
Nivolumab |
lung cancer |
||
Rigosertib |
myelodysplasia |
||
Enzalutamide |
prostate cancer |
||
Pembrolizumab |
melanoma |
||
regorafenib |
colorectal cancer |
||
Ipilimumab |
prostate cancer |
||
neratinib |
breast cancer |
Puma Biotechnology |
|
Vesigenurtacel-L |
bladder cancer |
||
Masitinib |
breast cancer |
||
Carfilzomib |
multiple myeloma |
Amgen |
|
Afatinib |
non-small cell lung cancer |
||
ThermoDox doxorubicin |
liver cancer |
||
Eribulin |
breast cancer |
Eisai |
|
Bortezomib |
myeloma |
Millennium Pharmaceuticals |
|
Vitamin D |
colorectal cancer |
Dana-Farber Cancer Institute |
|
Ramucirumab |
colorectal cancer |
Eli Lilly |
|
Talimogene laherparepvec |
melanoma |
Astrazeneca |
|
Afatinib |
lung cancer |
||
Nivolumab |
non-small cell lung cancer |
Bristol-Myers Squibb |
|
Obinutuzumab + chlorambucil |
cell lung carcinoma |
||
AGS-003 Dentritic cell immunotherapy |
renal cell carninoma |
Argos |
|
Entinostat |
breast cancer |
Syndax |
|
DCVax-L Dentritic cell immunotherapy |
glioblastoma |
Northwest Biotherapeutics |
|
Nabiximols |
cancer pain |
GW Pharmaceuticals |
|
cutirsen sodium |
Non-Small Cell Lung Cancer |
OncoGenex Pharmaceuticals |
|
hepcortespenlisimut-L |
hepatocellular carcinoma |
Immunitor |
|